| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA949: Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over |
|
Medicine details |
|
| Medicine name | belumosudil (Rezurock®) |
| Formulation | 200mg film coated tablet |
| Reference number | 5068 |
| Indication | Treatment of patients over the age of 12 with chronic graft-versus-host disease (cGvHD) after failure of at least two prior lines of systemic therapy |
| Company | Sanofi |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/03/2023 |
| NICE guidance | |